Published in Circulation on November 26, 2002
Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. J Cell Biol (2005) 3.14
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest (2008) 3.11
A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest (2012) 2.98
Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol (2013) 2.98
Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest (2003) 2.95
The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med (2003) 2.94
Diabetic neuropathy: mechanisms to management. Pharmacol Ther (2008) 2.57
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes (2008) 2.41
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 2.20
The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res (2010) 2.19
Macrophage deficiency of p38alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J Clin Invest (2009) 1.83
Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci (2011) 1.60
Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg (2009) 1.60
Diabetes complications: the microRNA perspective. Diabetes (2011) 1.60
PKCβ promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE null mice. Arterioscler Thromb Vasc Biol (2013) 1.52
Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med (Berl) (2009) 1.51
Retracted The effect of soluble RAGE on inhibition of angiotensin II-mediated atherosclerosis in apolipoprotein E deficient mice. PLoS One (2013) 1.47
Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord (2008) 1.40
RAGE signaling in inflammation and arterial aging. Front Biosci (Landmark Ed) (2009) 1.35
The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med (2009) 1.35
Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.32
Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care (2009) 1.30
Diabetic macrovascular disease: the glucose paradox? Circulation (2002) 1.29
Diabetic complications and dysregulated innate immunity. Front Biosci (2008) 1.28
Role of HMGB1 in cardiovascular diseases. Curr Opin Pharmacol (2006) 1.26
Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med (2009) 1.25
Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ Res (2010) 1.22
Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol (2010) 1.22
Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann N Y Acad Sci (2008) 1.17
Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med (2007) 1.14
Distinct roles of heterogeneous nuclear ribonuclear protein K and microRNA-16 in cyclooxygenase-2 RNA stability induced by S100b, a ligand of the receptor for advanced glycation end products. J Biol Chem (2008) 1.14
Role of advanced glycation end products in cardiovascular disease. World J Cardiol (2012) 1.13
Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes. Int J Vasc Med (2012) 1.12
RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med (2007) 1.11
Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies. Cardiovasc Res (2008) 1.10
Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease. J Alzheimers Dis (2013) 1.07
ERK and Akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cells. Int J Mol Med (2012) 1.07
How does the macula protect itself from oxidative stress? Mol Aspects Med (2012) 1.06
Molecular mechanisms of diabetic vascular complications. J Diabetes Investig (2010) 1.01
Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol (2010) 1.01
Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids (2010) 0.98
S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages. Clin Cancer Res (2013) 0.96
Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats. Aging Cell (2010) 0.96
Coronary microvascular dysfunction in diabetes mellitus: A review. World J Cardiol (2010) 0.96
High-mobility group box proteins modulate tumor necrosis factor-alpha expression in osteoclastogenesis via a novel deoxyribonucleic acid sequence. Mol Endocrinol (2008) 0.95
Sub-antimicrobial doxycycline for periodontitis reduces hemoglobin A1c in subjects with type 2 diabetes: a pilot study. Pharmacol Res (2011) 0.95
The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes. Front Endocrinol (Lausanne) (2012) 0.94
Morphological characteristics of coronary atherosclerosis in diabetes mellitus. Can J Cardiol (2006) 0.94
S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res (2012) 0.93
Statins stimulate the production of a soluble form of the receptor for advanced glycation end products. J Lipid Res (2013) 0.91
Mechanisms by which diabetes increases cardiovascular disease. Drug Discov Today Dis Mech (2007) 0.91
Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis. Acta Pharmacol Sin (2013) 0.90
Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data. Circulation (2010) 0.89
Precursor of advanced glycation end products mediates ER-stress-induced caspase-3 activation of human dermal fibroblasts through NAD(P)H oxidase 4. PLoS One (2010) 0.89
Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein. FASEB J (2007) 0.88
Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases. Future Neurol (2009) 0.87
RAGE mediates accelerated diabetic vein graft atherosclerosis induced by combined mechanical stress and AGEs via synergistic ERK activation. PLoS One (2012) 0.87
Urinary matrix metalloproteinase activities: biomarkers for plaque angiogenesis and nephropathy in diabetes. Am J Physiol Renal Physiol (2011) 0.87
Downregulation of an astrocyte-derived inflammatory protein, S100B, reduces vascular inflammatory responses in brains persistently infected with Borna disease virus. J Virol (2007) 0.87
Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases. Biomark Insights (2007) 0.87
Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes? Clin Biochem Rev (2005) 0.86
Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study. Am Heart J (2015) 0.85
Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice. Br J Cancer (2007) 0.85
Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway. Clin Pharmacol Ther (2015) 0.85
Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes. Curr Diab Rep (2009) 0.84
Role of Advanced Glycation End Products and Its Receptors in the Pathogenesis of Cigarette Smoke-Induced Cardiovascular Disease. Int J Angiol (2015) 0.84
Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products. Biochim Biophys Acta (2011) 0.83
Cellular mechanisms and consequences of glycation in atherosclerosis and obesity. Biochim Biophys Acta (2016) 0.83
Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients. Int J Angiol (2009) 0.82
Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection. J Infect Dis (2012) 0.81
AGEs induce cell death via oxidative and endoplasmic reticulum stresses in both human SH-SY5Y neuroblastoma cells and rat cortical neurons. Cell Mol Neurobiol (2012) 0.81
Levels of Soluble Receptor for Advanced Glycation End Products in Acute Ischemic Stroke without a Source of Cardioembolism. J Clin Neurol (2009) 0.81
The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood. Pediatr Nephrol (2011) 0.81
Elevation of high-mobility group box 1 after clinical autologous islet transplantation and its inverse correlation with outcomes. Cell Transplant (2012) 0.80
Association of four genetic polymorphisms of AGER and its circulating forms with coronary artery disease: a meta-analysis. PLoS One (2013) 0.80
Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary Syndrome. Biomed Res Int (2015) 0.79
Advanced glycation end products and C-peptide-modulators in diabetic vasculopathy and atherogenesis. Semin Immunopathol (2009) 0.79
The role of glucosamine-induced ER stress in diabetic atherogenesis. Exp Diabetes Res (2012) 0.79
Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management. Diabetes Metab Syndr Obes (2015) 0.79
Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome. PLoS One (2013) 0.78
Senescence-dependent impact of anti-RAGE antibody on endotoxemic liver failure. Age (Dordr) (2013) 0.78
Reasons to Investigate the Soluble Receptor for Advanced Glycation End-Product (sRAGE) Pathway in Aortic Disease. Aorta (Stamford) (2013) 0.78
Exercise mediated protection of diabetic heart through modulation of microRNA mediated molecular pathways. Cardiovasc Diabetol (2017) 0.78
Impact of hyperglycemia and acute pancreatitis on the receptor for advanced glycation endproducts. Int J Clin Exp Pathol (2013) 0.77
Imaging RAGE expression in atherosclerotic plaques in hyperlipidemic pigs. EJNMMI Res (2014) 0.77
Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting Endoplasmic Reticulum (ER) Stress Induced by Disturbed Flow. Mol Cells (2015) 0.77
PREMATURE VASCULAR SENESCENCE IN METABOLIC SYNDROME: COULD IT BE PREVENTED AND REVERSED BY A SELENORGANIC ANTIOXIDANT AND PEROXYNITRITE SCAVENGER EBSELEN? Drug Discov Today Ther Strateg (2007) 0.77
Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH. PLoS One (2014) 0.77
Protective effect of mangiferin on myocardial ischemia-reperfusion injury in streptozotocin-induced diabetic rats: role of AGE-RAGE/MAPK pathways. Sci Rep (2017) 0.77
GeneOptimizer program-assisted cDNA reengineering enhances sRAGE autologous expression in Chinese hamster ovary cells. Protein Expr Purif (2013) 0.77
Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy. J Ophthalmol (2010) 0.76
Advanced glycation end products increase lipids accumulation in macrophages through upregulation of receptor of advanced glycation end products: increasing uptake, esterification and decreasing efflux of cholesterol. Lipids Health Dis (2016) 0.75
Isolevuglandin-type lipid aldehydes induce the inflammatory response of macrophages by modifying phosphatidylethanolamines and activating the receptor for advanced glycation endproducts. Antioxid Redox Signal (2015) 0.75
Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products. Endocrine (2015) 0.75
Vessel ultrasound sonographic assessment of soluble receptor for advanced glycation end products efficacy in a rat balloon injury model. Curr Ther Res Clin Exp (2014) 0.75
Beneficial Effect of Glucose Control on Atherosclerosis Progression in Diabetic ApoE(-/-) Mice: Shown by Rage Directed Imaging. Int J Mol Imaging (2014) 0.75
Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting RAGE Signaling in Diabetic Atherosclerosis. PLoS One (2016) 0.75
Relationship between serum levels of endogenous secretory RAGE and blood pressure in male nondiabetic patients with obstructive sleep apnea. J Hum Hypertens (2015) 0.75
Advanced glycation end products impair the functions of saphenous vein but not thoracic artery smooth muscle cells through RAGE/MAPK signalling pathway in diabetes. J Cell Mol Med (2016) 0.75
DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature (2007) 13.56
Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation (2006) 5.31
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol (2005) 4.99
Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) (2005) 4.96
Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest (2004) 4.04
Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res (2004) 4.00
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature (2009) 3.86
A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A (2003) 3.82
Professional antigen-presentation function by human gammadelta T Cells. Science (2005) 3.77
Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med (2009) 3.70
Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med (2012) 3.31
Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc Natl Acad Sci U S A (2008) 3.27
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest (2008) 3.11
Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol (2006) 3.03
The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest (2005) 2.80
Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol (2006) 2.75
Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology (2005) 2.74
Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood (2003) 2.73
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain (2010) 2.41
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A (2006) 2.31
Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol (2004) 2.30
Angiographic estimates of myocardium at risk during acute myocardial infarction: validation study using cardiac magnetic resonance imaging. Eur Heart J (2007) 2.26
Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res (2003) 2.25
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 2.20
The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res (2010) 2.19
Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation (2002) 2.18
Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2003) 2.17
Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst (2008) 2.15
The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation (2003) 2.14
Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab (2008) 2.13
Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology (2007) 2.11
RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J (2004) 2.08
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood (2009) 2.06
S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem (2003) 2.05
Chemical manipulation of hsp70 ATPase activity regulates tau stability. J Neurosci (2009) 2.05
Homing and function of human skin gammadelta T cells and NK cells: relevance for tumor surveillance. J Immunol (2006) 2.02
Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem (2008) 1.97
Identification, classification, and expression of RAGE gene splice variants. FASEB J (2007) 1.96
Impaired tRNA nuclear export links DNA damage and cell-cycle checkpoint. Cell (2007) 1.94
Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res (2008) 1.94
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest (2004) 1.92
A skin-selective homing mechanism for human immune surveillance T cells. J Exp Med (2004) 1.91
ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J (2005) 1.89
The relationship between oral health and diabetes mellitus. J Am Dent Assoc (2008) 1.88
DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale. Nucleic Acids Res (2013) 1.86
Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis (2012) 1.84
RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts. J Leukoc Biol (2009) 1.84
Advanced glycation end product recognition by the receptor for AGEs. Structure (2011) 1.84
Integrating gene and protein expression data: pattern analysis and profile mining. Methods (2005) 1.83
Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin Cancer Res (2009) 1.83
A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res (2007) 1.80
Estimation of distribution algorithm for resource allocation in green cooperative cognitive radio sensor networks. Sensors (Basel) (2013) 1.79
Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology (2004) 1.77
Candidate lung tumor susceptibility genes identified through whole-genome association analyses in inbred mice. Nat Genet (2006) 1.77
Protein glycation: a firm link to endothelial cell dysfunction. Circ Res (2004) 1.76
RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci U S A (2009) 1.74
Reciprocal generation of Th1/Th17 and T(reg) cells by B1 and B2 B cells. Eur J Immunol (2007) 1.70
Correspondence between the 17-segment model and coronary arterial anatomy using contrast-enhanced cardiac magnetic resonance imaging. JACC Cardiovasc Imaging (2008) 1.70
RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis (2005) 1.67
Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci (2008) 1.67
Multiplex PCR assay for identification of human diarrheagenic Escherichia coli. J Clin Microbiol (2003) 1.66
Circulating CD34-positive cells provide an index of cerebrovascular function. Circulation (2004) 1.66
Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ T(H)2 cells. Nat Immunol (2011) 1.66
Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα. J Clin Invest (2014) 1.66
The mitochondrial pathway of anesthetic isoflurane-induced apoptosis. J Biol Chem (2009) 1.64
In vivo tracking of 'color-coded' effector, natural and induced regulatory T cells in the allograft response. Nat Med (2010) 1.63
Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med (2003) 1.62
The inhalation anesthetic isoflurane increases levels of proinflammatory TNF-α, IL-6, and IL-1β. Neurobiol Aging (2010) 1.62
Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet (2010) 1.62
Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci U S A (2009) 1.61